Neochem Bio Solutions Ltd (NEOCHEM) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed guidance for over 40% revenue growth in FY27 and a sustained CAGR of 40%+ over the next 5-6 years.
- The company expects gross margins to recover to around 33% in H2, up from the 30-31% level seen in H1.
- Receivable days are targeted to be below 120 by March 2027, with operating cash flow expected to turn positive for the full year.
Performance Overview
- Revenue from operations for H1 FY27 grew 50% year-on-year, significantly ahead of the 30% growth commitment.
- EBITDA margins held at 18%, which is within the company's guided range of 18-20%, despite raw material cost pressures.
- Significant improvement in working capital management, with receivable days reduced from 161 to 128 in H1.
- Operating cash flow improved dramatically from a negative INR 17 crores in FY26 to nearly neutral at negative INR 1 crore in H1 FY27.
- The leadership team was strengthened with key appointments, including a new Chief Commercial Officer and Chief Financial Officer, to support future growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.